Welcome to our dedicated page for AngioDynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on AngioDynamics stock.
Founded in 1988 in Queensbury, N.Y., U.S., AngioDynamics, Inc. (NASDAQ: ANGO) is a leading provider of innovative medical devices that serve interventional radiologists, nephrologists, and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. The company's product portfolio includes market-leading systems such as the NanoKnife® system, radiofrequency ablation devices, and a variety of vascular access, angiographic, dialysis, angioplasty, and embolization products.
AngioDynamics has a strong track record of developing and bringing new technologies to market, maintaining a dynamic presence in the high-growth medical device industry. Recently, the company reported net sales of $78.7 million for the first quarter of fiscal year 2024, including a 13.3% increase in Med Tech net sales driven by the NanoKnife platform. AngioDynamics also completed the sale of its Dialysis and BioSentry Biopsy Tract Sealant System businesses, significantly enhancing its financial flexibility.
In addition to financial growth, AngioDynamics continues to innovate with significant developments such as the APEX-AV study, aimed at evaluating the safety and efficacy of the AlphaVac F1885 System for treating acute pulmonary embolism. The company’s AlphaVac F1885 System has recently received FDA clearance for the treatment of pulmonary embolism, a significant milestone that expands its indication in critical medical scenarios.
With ongoing plans to transition to a fully outsourced manufacturing model and recent divestitures to streamline its portfolio, AngioDynamics is well-positioned to focus on its core strengths and drive long-term profitability. The company's net sales are projected to be between $328 to $333 million for fiscal year 2024, with an anticipated improved gross margin and reduced adjusted loss per share.
AngioDynamics (ANGO) reported Q4 fiscal 2021 net sales of $76.8 million, up 31.7% year-over-year. Endovascular Therapies saw a 72.3% increase, driven by Auryon and AngioVac sales, while oncology sales rose 14.2%. Despite these gains, the company incurred a net loss of $19.5 million, including a $14.0 million write-off. For FY 2021, net sales reached $291.0 million, a 10.2% increase, but net loss was $31.5 million. Looking ahead, FY 2022 guidance estimates net sales of $305 to $310 million and adjusted EPS of $0.00 to $0.05, reflecting ongoing investment in product launches.
AngioDynamics (NASDAQ: ANGO) announced its upcoming virtual Investor & Technology Day on July 13, from 9:30 to 11:30 a.m. ET. The event will feature presentations from the executive leadership team, discussing the company’s growth strategy, key technology platforms, and financial goals. Interested parties can register via the company’s website. A live webcast and archive of the presentation will also be available on the Investors section of the AngioDynamics website.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q4 and fiscal year 2021 on July 13, 2021, before market open. A conference call is scheduled for 8:00 a.m. ET for management to discuss these results. Investors can dial in using a specified number or access through a webcast on the company's website. Additionally, AngioDynamics will host a virtual Investor & Technology Day on the same day at 9:30 a.m. ET. Details and registration information will be provided on their website.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that it received 510(k) clearance from the FDA for the AlphaVac Mechanical Thrombectomy System, designed for non-surgical removal of thrombi or emboli. The commercial release is anticipated in the second half of 2021. Additionally, the Company will report its fourth quarter and fiscal year 2021 financial results on July 13, 2021, with a conference call scheduled at 8:00 a.m. ET, followed by a virtual Investor and Technology Day at 9:30 a.m. ET.
AngioDynamics, Inc. (NASDAQ: ANGO), a top provider of minimally invasive medical devices, announced Jim Clemmer, President and CEO, will present at the UBS Virtual Global Healthcare Conference on May 25, 2021, at 12:00 p.m. ET. The live webcast can be accessed through the company’s website and will be available for replay afterward.
The company specializes in devices for vascular access, peripheral vascular disease, and oncology, with a product range that includes ablation systems and drainage products. For further details, visit www.angiodynamics.com.
AngioDynamics (NASDAQ: ANGO) announced the submission of a 510(k) application to the FDA for its AlphaVac System on April 9, 2021. This innovative thrombectomy device aims to treat undesirable intravascular materials in the venous system and peripheral vasculature. The AlphaVac System combines a mechanical aspiration handle with a self-expanding funnel tip, enhancing control and minimizing blood loss during procedures. The company anticipates the release of AlphaVac in the latter half of 2021, pending FDA clearance, as part of its strategy to expand its thrombus management portfolio.
AngioDynamics (NASDAQ:ANGO), a leader in minimally invasive medical devices, announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the Needham Virtual Healthcare Conference on April 12, 2021, at 8:45 a.m. ET. Investors can access the live webcast through AngioDynamics’ website, where a replay will also be available post-event. The company specializes in products for vascular access, peripheral vascular disease, and oncology, including ablation systems and vascular access products.
AngioDynamics (NASDAQ: ANGO) reported its third-quarter fiscal 2021 financial results, showing a 2% year-over-year revenue growth to $71.2 million, despite COVID-19 challenges. Vascular Interventions and Therapies sales increased by 8.8% to $33.3 million. However, Oncology sales dropped by 10.1% to $13.1 million. The company recorded a net loss of $3.5 million, improving from a $5.7 million loss last year. The gross margin declined to 54.1% due to Auryon start-up costs and COVID-related impacts. Adjusted guidance for FY2021 is now $285-$288 million in sales.
AngioDynamics (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will take part in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum. The event is scheduled for 10:00 a.m. ET on March 24, 2021. Investors can access a live webcast through the company’s website, with replay availability post-event. AngioDynamics specializes in minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, offering a range of leading products.
AngioDynamics, Inc. (NASDAQ: ANGO) announces participation in a virtual fireside chat at the 31st Annual Oppenheimer Healthcare Conference. Scheduled for March 16, 2021, at 9:20 a.m. ET, CEO Jim Clemmer and CFO Stephen Trowbridge will discuss company insights. A live webcast will be available through the Company’s website, with replay options post-event. AngioDynamics specializes in innovative, minimally invasive medical devices for vascular access, oncology, and peripheral vascular disease, focusing on diverse product lines that enhance patient care.
FAQ
What is the current stock price of AngioDynamics (ANGO)?
What is the market cap of AngioDynamics (ANGO)?
What does AngioDynamics, Inc. specialize in?
What are some recent achievements of AngioDynamics, Inc.?
What is the AlphaVac F1885 System?
What financial performance did AngioDynamics report for the first quarter of fiscal year 2024?
What are AngioDynamics' future plans for manufacturing?
Where does AngioDynamics generate the majority of its revenue?
What is the NanoKnife® system?
How does AngioDynamics plan to enhance its focus on core strengths?
What is the APEX-AV study?
How does AngioDynamics contribute to the medical device industry?
